Skip to main content
Zensei
Beating the market and pharmaceutical stocks

Pfizer (PFE) stock vs the S&P 500 and pharmaceutical stocks

As of 20 November 2026, Pfizer (PFE) is beating both the S&P 500 and pharmaceutical stocks as a group (PPH) over the past three months.

Prices as of Last update : Beating the market, trailing pharmaceutical stocks → beating the market and pharmaceutical stocks
PFE 1M
−7.7%
S&P 500 1M
−10.3%
Funds that hold it
3
Weight in PPH
5.1%

Where Pfizer stands now

As of 20 November 2026, Pfizer is ahead of the S&P 500 on every window Zensei tracks, from one month to one year. The trend against the market is intact on all horizons.

Inside its group, PFE is slipping: still ahead of pharmaceutical stocks (PPH) over three months, but behind over the past month. As a group, pharmaceutical stocks are gaining ground on the S&P 500 right now. The group is in transition, so the stock's place inside it matters more than usual.

Pfizer is 5.1% of PPH, so its moves weigh on the fund. It sits in 3 of the sector and theme funds Zensei tracks. The thing to watch is the gap to its group: as long as it stays ahead of both the market and its peers, the trend is intact.

PFE vs the S&P 500: returns

Pfizer and the S&P 500 (SPY) side by side, over each window Zensei tracks.

Window
PFE
S&P 500
1 week−5.2%−8.6%
2 weeks−7.0%−5.9%
1 month−7.7%−10.3%
3 months−1.0%−9.7%
6 months+9.2%−7.0%
1 year+19.9%+6.9%

Prices as of · computed from daily adjusted closes · how we measure

Zensei Edge

PFE against pharmaceutical stocks, in depth

See the size of the gap between Pfizer and pharmaceutical stocks (PPH) over every window, its momentum and its relative strength, and where it sits among pharmaceutical stocks.

See the full analysis

Which ETFs hold Pfizer?

3 funds that Zensei tracks hold PFE, by weight. The fund with the largest weight is its sector on this page.

Fund
Weight
PPHPharmaceutical StocksMain sector
VanEck Pharmaceutical ETF
5.1%
Health Care Select Sector SPDR
2.6%
SPDR S&P 1500 Momentum Tilt ETF
0.35%

Pfizer competitors

The largest other holdings of VanEck Pharmaceutical ETF (PPH), with their return over the past month.

Stock
Weight
1M
23.2%+5.1%
MRKMerck & Co Inc
12.5%−9.8%
5.5%−3.9%
MCKMckesson Corp
4.7%+3.8%
BMYBristol-Myers Squibb Co
4.5%−4.7%
CORCencora Inc
4.3%−1.0%
GSKGsk PLC
4.2%−4.8%
NVSNovartis AG
3.8%−2.1%
Each stock measured against the sector, with momentum and relative strengthUnlock with Premium

Pfizer stock: common questions

Is Pfizer stock beating the S&P 500?

As of 20 November 2026, Pfizer (PFE) is down 7.7% over the past month. The S&P 500 is down 10.3% over the same month. Over three months, the stock is down 1.0% and the S&P 500 is down 9.7%.

Which ETFs hold Pfizer?

As of 20 November 2026, 3 funds that Zensei tracks hold PFE. Its largest weight is in VanEck Pharmaceutical ETF (PPH), at 5.1%. It is also in Health Care Select Sector SPDR (XLV, 2.6%), SPDR S&P 1500 Momentum Tilt ETF (MMTM, 0.4%).

Who are Pfizer's competitors?

As of 20 November 2026, the largest other holdings of VanEck Pharmaceutical ETF (PPH) are Eli Lilly (LLY), Merck & Co Inc (MRK), Novo Nordisk (NVO), Mckesson Corp (MCK), Bristol-Myers Squibb Co (BMY). These are the stocks Pfizer sits next to among pharmaceutical stocks.

Is Pfizer doing better than other pharmaceutical stocks?

As of 20 November 2026, Pfizer (PFE) is ahead of pharmaceutical stocks as a group (PPH) over the past three months. Zensei Edge shows the size of the gap, its momentum and its relative strength.

Recent changes

  1. ·Beating the market, trailing pharmaceutical stocks → beating the market and pharmaceutical stocks
  2. ·Beating the market and pharmaceutical stocks → beating the market, trailing pharmaceutical stocks
  3. ·Among the strongest → beating the market and pharmaceutical stocks
  4. ·Beating the market and pharmaceutical stocks → among the strongest
  5. ·Among the strongest → beating the market and pharmaceutical stocks

Track Pfizer against pharmaceutical stocks and the market

Zensei Edge maps 100+ sectors and themes against the S&P 500, with each stock inside them measured against its group.